ACER THERAPEUTICS INC (ACER) Fundamental Analysis & Valuation
NASDAQ:ACER • US00444P1084
Current stock price
0.9 USD
+0.03 (+3.41%)
At close:
0.8005 USD
-0.1 (-11.06%)
After Hours:
This ACER fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. ACER Profitability Analysis
1.1 Basic Checks
- In the past year ACER has reported negative net income.
- ACER had a negative operating cash flow in the past year.
1.2 Ratios
- ACER's Return On Assets of -225.71% is on the low side compared to the rest of the industry. ACER is outperformed by 92.72% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -225.71% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)-141.6%
ROA(5y)-120.76%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- ACER does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. ACER Health Analysis
2.1 Basic Checks
- ACER does not have a ROIC to compare to the WACC, probably because it is not profitable.
- Compared to 1 year ago, ACER has more shares outstanding
- ACER has a worse debt/assets ratio than last year.
2.2 Solvency
- ACER has an Altman-Z score of -25.07. This is a bad value and indicates that ACER is not financially healthy and even has some risk of bankruptcy.
- With a Altman-Z score value of -25.07, ACER is not doing good in the industry: 91.75% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | -25.07 |
ROIC/WACCN/A
WACC9.13%
2.3 Liquidity
- ACER has a Current Ratio of 0.19. This is a bad value and indicates that ACER is not financially healthy enough and could expect problems in meeting its short term obligations.
- With a Current ratio value of 0.19, ACER is not doing good in the industry: 97.09% of the companies in the same industry are doing better.
- A Quick Ratio of 0.19 indicates that ACER may have some problems paying its short term obligations.
- ACER has a Quick ratio of 0.19. This is amonst the worse of the industry: ACER underperforms 96.12% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.19 | ||
| Quick Ratio | 0.19 |
3. ACER Growth Analysis
3.1 Past
- ACER shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -88.64%.
- The Revenue for ACER has decreased by -100.00% in the past year. This is quite bad
EPS 1Y (TTM)-88.64%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-74.19%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-100%
3.2 Future
- ACER is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 35.01% yearly.
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y55.45%
EPS Next 2Y44%
EPS Next 3Y35.01%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. ACER Valuation Analysis
4.1 Price/Earnings Ratio
- ACER reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
- Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ACER. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- ACER's earnings are expected to grow with 35.01% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y44%
EPS Next 3Y35.01%
5. ACER Dividend Analysis
5.1 Amount
- ACER does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
ACER Fundamentals: All Metrics, Ratios and Statistics
0.9
+0.03 (+3.41%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-15 2023-11-15/amc
Earnings (Next)03-25 2024-03-25/amc
Inst Owners1.19%
Inst Owner Change0%
Ins Owners0.02%
Ins Owner Change0%
Market Cap22.01M
Revenue(TTM)N/A
Net Income(TTM)-26.24M
Analysts80
Price Target1.53 (70%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)6.22%
Min EPS beat(2)-43.08%
Max EPS beat(2)55.52%
EPS beat(4)2
Avg EPS beat(4)8%
Min EPS beat(4)-51.19%
Max EPS beat(4)70.76%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-86.36%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)-6.62%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-16.17%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | N/A | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | N/A |
EPS(TTM)-1.66
EYN/A
EPS(NY)-0.74
Fwd EYN/A
FCF(TTM)-1.24
FCFYN/A
OCF(TTM)-1.24
OCFYN/A
SpS0
BVpS-0.69
TBVpS-1
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -225.71% | ||
| ROE | N/A | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-141.6%
ROA(5y)-120.76%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score0
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 259.19% | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.19 | ||
| Quick Ratio | 0.19 | ||
| Altman-Z | -25.07 |
F-Score0
WACC9.13%
ROIC/WACCN/A
Cap/Depr(3y)116.99%
Cap/Depr(5y)196.86%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-88.64%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-74.19%
EPS Next Y55.45%
EPS Next 2Y44%
EPS Next 3Y35.01%
EPS Next 5YN/A
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-100%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-91.58%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-15924.8%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-22323.8%
OCF growth 3YN/A
OCF growth 5YN/A
ACER THERAPEUTICS INC / ACER Fundamental Analysis FAQ
Can you provide the ChartMill fundamental rating for ACER THERAPEUTICS INC?
ChartMill assigns a fundamental rating of 0 / 10 to ACER.
What is the valuation status of ACER THERAPEUTICS INC (ACER) stock?
ChartMill assigns a valuation rating of 1 / 10 to ACER THERAPEUTICS INC (ACER). This can be considered as Overvalued.
What is the profitability of ACER stock?
ACER THERAPEUTICS INC (ACER) has a profitability rating of 0 / 10.
Can you provide the financial health for ACER stock?
The financial health rating of ACER THERAPEUTICS INC (ACER) is 0 / 10.
What is the earnings growth outlook for ACER THERAPEUTICS INC?
The Earnings per Share (EPS) of ACER THERAPEUTICS INC (ACER) is expected to grow by 55.45% in the next year.